Lilly files six lawsuits targeting sellers of unapproved retatrutide

Eli Lilly filed six federal lawsuits on August 12 against U.S. businesses it accuses of selling products represented as retatrutide, an investigational metabolic drug that no regulator has approved for human use.

The defendants named by Lilly are Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide. The group includes online peptide vendors, a compounding pharmacy and a medical spa. Lilly also called on payment processors, online platforms and shipping companies to stop supporting sellers of purported retatrutide.

The filings matter beyond one drug candidate. They directly challenge a recurring strategy in the online peptide market: labeling a product “research use only” while allegedly promoting or facilitating its use by consumers.

What the complaints allege

In its complaint against Legendary Peptides, Lilly alleges that the company’s research label was a pretext and that its marketing, consumer sales and social-media activity demonstrated an intended human use. The complaint seeks an injunction against further marketing or distribution, monetary relief and legal costs.

Those statements remain allegations. The complaints were newly filed, the defendants have not had their claims adjudicated, and no court has determined liability. A complaint documents what a plaintiff asserts and the evidence it intends to develop; it is not a regulatory finding or a final judgment.

Lilly’s broader campaign is unusually expansive. The company said it has referred more than 200 individuals and entities to regulators, law-enforcement agencies and licensing boards. It also reported more than 14,000 websites, advertisements, social posts and product listings in more than 100 countries. Those figures are company-reported and have not been independently audited in the court record reviewed for this article.

FDA’s position is separate from Lilly’s case

The regulatory baseline does not depend on whether Lilly wins these lawsuits. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law because they are not components of approved drugs and have not been found safe and effective for any condition.

FDA also warns that products containing retatrutide have been sold directly to consumers under “research purposes” or “not for human consumption” labels while providing dosing instructions. The agency describes those products as being of unknown quality and potentially harmful.

This is narrower than saying all pharmacy compounding is unlawful. Federal law permits compounding in defined circumstances, and FDA recognizes that a compounded medicine can be appropriate when an individual patient’s medical need cannot be met by an approved product. Retatrutide does not currently qualify for that pathway.

An investigational drug with a commercial shadow

Retatrutide is a once-weekly peptide designed to activate GIP, GLP-1 and glucagon receptors. Lilly is studying it in Phase 3 trials across obesity, type 2 diabetes and related cardiometabolic conditions. The company reported additional positive topline Phase 3 results on July 23 and said it plans to submit a biologics license application in the first quarter of 2027.

Topline announcements are not regulatory approvals. Detailed results, complete safety analyses and regulatory review still matter, and a product sold outside Lilly’s controlled trials cannot be assumed to match the investigational material used in those studies.

What remains unresolved

The litigation does not establish what was inside any particular vial, whether every defendant used the same manufacturing source, or whether alleged adverse events were caused by retatrutide, contaminants, dosing errors or unrelated factors. At least one reviewed complaint relies partly on marketing materials and online anecdotes rather than independent testing of the defendant’s product.

Lilly also has an evident commercial interest in protecting a late-stage candidate. That does not alter FDA’s independent position, but it should shape how readers interpret the company’s descriptions of market size, harm and urgency.

For clinicians and editors, the practical distinction is straightforward: retatrutide remains an investigational therapy, not an approved or lawfully compounded alternative to existing metabolic drugs. The lawsuits may test how effectively consumer-protection and unfair-competition laws can reach sellers operating behind research disclaimers, but their legal outcome remains open.